Phathom Pharmaceuticals Inc (PHAT NASDAQ) stock market data APIs
$18.215
-1.72(-9.4%)
as of January 7, 2026
Try our APIs with
free plan!
Phathom Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Prev. Close
18.215
Open
16.4924
High
18.2421
Low
16.3994
52 wk Range
2.21-18.31
Market Cap
1 165 M
Shares Outstanding
71 138 K
Revenue
147 M
EPS
-0.15
Beta
0.486
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Phathom Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Phathom Pharmaceuticals Inc data using free add-ons & libraries
Get Phathom Pharmaceuticals Inc Fundamental Data
Phathom Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 147 M
- EBITDA: -212 776 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.47
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phathom Pharmaceuticals Inc News
New
Phathom Pharma plans public offering after reporting preliminary 2025 results
* Phathom Pharmaceuticals (PHAT [https://seekingalpha.com/symbol/PHAT]) said on Wednesday it plans a public offering of common stock and pre-funded warrants, subject to market conditions, shortly af...
Shaya Prager Announces Opal Holdings Leasing Activity of 250,000 Square Feet Across Portfolio in 2025
CHICAGO and NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Opal Holdings LLC ("Opal"), a national commercial real estate owner and operator founded by Shaya Prager, announced today that it has successfully e...
After-Hours Gainers: GH Research, Phathom, Forte, OKYO, Zai Lab, LifeMD, Werewolf & Corvus Rally
(RTTNews) - Biotech names dominated the after-hours session on Friday, with several companies posting notable gains despite limited news catalysts. GH Research PLC (GHRS) surged the most, climbing 22...
Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks
As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed a simple script. Policy uncertainty lingered, and trade headlines remained ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
